A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis

Trial Profile

A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Ipilimumab (Primary) ; Fotemustine
  • Indications Brain metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms NIBIT-M2
  • Most Recent Events

    • 29 May 2015 According to an abstract presented at 51st Annual Meeting of the American Society of Clinical Oncology 17 patients have been enrolled till date.
    • 29 May 2015 Trial design presented at 51st Annual Meeting of the American Society of Clinical Oncology.
    • 10 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top